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Abstract
Background: Oral polio vaccine (OPV) is recommended to be given at birth together with BCG vaccine. While we were
conducting two trials including low-birth-weight (LBW) and normal-birth-weight (NBW) infants in Guinea-Bissau, OPV was
not available during some periods and therefore some infants did not receive OPV at birth, but only BCG. We investigated
the effect of OPV given simultaneously with BCG at birth on the immune response to BCG vaccine.
Methods and Findings: We compared the in vitro and the in vivo response to PPD in the infants who received OPV and BCG
with that of infants who received BCG only. At age 6 weeks, the in vitro cytokine response to purified protein derivate (PPD)
of M. Tuberculosis was reduced in LBW and NBW infants who had received OPV with BCG. In a pooled analysis receiving OPV
with BCG at birth was associated with significantly lower IL-13 (p=0.041) and IFN-c (p=0.004) and a tendency for lower IL-
10 (p=0.054) in response to PPD. Furthermore, OPV was associated with reduced in vivo response to PPD at age 2 months,
the prevalence ratio (PR) of having a PPD reaction being 0.75 (0.58–0.98), p=0.033, and with a tendency for reduced
likelihood of having a BCG scar (0.95 (0.91–1.00), p=0.057)). Among children with a scar, OPV was associated with reduced
scar size, the regression coefficient being 20.24 (20.43—0.05), p=0.012.
Conclusions: This study is the first to address the consequences for the immune response to BCG of simultaneous
administration with OPV. Worryingly, the results indicate that the common practice in low-income countries of
administering OPV together with BCG at birth may down-regulate the response to BCG vaccine.
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Introduction
WHO recommends BCG vaccine and oral polio vaccine (OPV)
at birth in low-income countries. BCG vaccine is the world’s most
widely used vaccine and although its efficacy is variable, it is still
considered the best way to protect against childhood tuberculosis
[1,2]. BCG vaccination induces potent Th1 responses to mycobac-
terial antigen in newborns [3]. Studies in Gambia have shown that
BCG vaccination affects responses to unrelated vaccines by
enhancing the production of Th1 and Th2 type cytokines [3,4].
BCG vaccination in early life also increased the antibody response
to OPV [4]. The effect of providing OPV simultaneously with BCG
on the immune response to BCG has never been studied.
We recently conducted two trials among newborns in Guinea-
Bissau. According to local practice, low-birth-weight (LBW,
,2500 g) infants only receive OPV at birth; BCG vaccine is
usually postponed until the child reaches 6 weeks of age. In trial 1,
LBW infants were randomized to receive an early BCG vaccine or
the usual delayed BCG vaccine. In trial 2, normal birth-weight
(NBW, $2500 g) children were randomized to vitamin A
supplementation or placebo together with BCG vaccine [5]. The
children were followed for mortality. Subgroups of the children
were also followed for the in vivo and in vitro immune response to
BCG [6]. OPV is recommended to be given at birth but for
certain periods in 2004, during the conduct of the two trials, OPV
was not available in Guinea-Bissau and hence some trial
participants did not receive OPV at birth. This ‘natural
experiment’ allowed us to compare in an observational, but rather
unbiased manner, the effect of OPV provided with BCG at birth.
Intriguingly, we observed that not receiving OPV at birth was
associated with significantly decreased male mortality during the
first year of life [7]. In the present study we investigated the effect
of OPV given simultaneously with BCG at birth on the immune
response to BCG vaccine.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
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and for European Centers by the Danish Central Ethical
Committee. All mothers provided written informed consent for
the collection of samples of their children.
Setting
The two large randomized trials were conducted by the Bandim
Health Project (BHP) in Bissau, Guinea-Bissau. The BHP covers a
population of around 100,000 in 6 districts in the urban area by a
demographicsurveillancesystem.Allhousesarevisitedeverymonth
to register new pregnancies and births. Once a newborn is
identified, the child is followed with a home visit every third month.
There is a national hospital (NH) with a maternity ward in the
capital andthree healthcentersinthestudyarea, one ofthem witha
maternity ward. Around 60–70% of the mothers from the study
area deliver at the NH or at the health center maternity ward. Since
2002 all LBW infants born at the NH have been followed for one
year, also infants outside the study area. In trial 1, all LBW infants
born at the NH or in the study area were invited to participate in a
trial studying the effect of receiving early BCG vaccination on
mortality and cytokine levels in LBW infants. In trial 2, NBW
infants from the study area were invited to participate in a trial
studying the effect of vitamin A supplementation at birth on
mortality and cytokine levels. These two EU funded trials were
carried outwithinacollaborativenetworkofEuropeanand Guinea-
Bissau institutions. The trials were registered at www.clinicaltrials.
gov, registration number, NCT00146302 and NCT00168597.
Enrolment into the trials
Newborns were enrolled throughout 2004 (Figure 1). Mothers
were informed of the purpose of the study. If a mother of a LBW
infant accepted to participate, she drew a randomization number
indicating whether the children would be BCG vaccinated early or
not. If a mother of a NBW infant accepted to participate, she drew
a randomization number indicating whether the children would
receive vitamin A supplementation (50,000 IU) or placebo. At the
time of enrolment, children were examined clinically. The infants
were weighed and length, head-circumference and mid-upper-
arm-circumference (MUAC) were measured. Newborns that were
overtly ill were not enrolled but referred to treatment.
LBW infants who were randomized to not receiving early BCG
vaccination were not included in the present study since we aimed
to look at the effect of OPV on the immune response to BCG
given at the same time. Hence, the LBW population only includes
children who were randomized to BCG at birth. NBW children
who had received vitamin A supplementation at birth were not
included in the present study as this could have affected their
response to OPV and BCG. Hence, the NBW population only
includes children who were randomized to placebo at birth.
Vaccines
BCG (0.05 ml; Statens Serum Institut, Copenhagen, Denmark)
was provided by the BHP and given intradermally in the upper left
deltoid region. OPV was supplied through the national immuni-
zation programme and given orally. Three types of OPV were
used in Guinea-Bissau, produced by Novartis, Sanofi Pasteur, and
GlaxoSmithKline. However, OPV was missing during periods of
2004. As part of our trial routines, we noted at the inclusion form
whether the children received OPV or not. Based on the
distribution of children who had not received OPV, OPV was
missing at one or more inclusion sites 1) from the beginning of
February 2004 to the beginning of June 2004, 2) again in the end
of June 2004, and 3) from the end of October 2004 to November
2004 (Figure 1).
Figure 1. An overview of the two trials, the periods with missing OPV, and the periods with ongoing subgroup studies in Guinea-
Bissau 2004.
doi:10.1371/journal.pone.0010328.g001
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We aimed to enroll 200 children from trial 1 and 400 children
from trial 2 in a subgroup study of cytokine production. The
children were enrolled between April and November 2004
(Figure 1). We attempted to visit the children at 6 weeks of age. A
blood sample was collected by finger prick and analyzed for in vitro
cytokine responses. Whole blood cultures were done as previously
described [6,8]. Briefly, heparinized finger prick blood was diluted
in RPMI 1640 medium (Invitrogen, Breda, The Netherlands) to a
final concentration of 1 in 10 and culture in a total volume of 200 ml
in 96-well U plate (Nunc, Roskilde, Denmark) with the presence of
purified protein derivative of Mycobacterium tuberculosis (PPD, 10 mg/
ml; Statens Serum Institut, Denmark, Copenhagen). Supernatants
were collected on day 3 and stored at 280uC.
Measurement of cytokine levels
IL-5, IL-10, IL-13, IFN-c and TNF-a from day 3 supernatants
were analyzed simultaneously using commercial Luminex
cytokine kit and buffer reagent kit (BioSource, Camarillo, CA,
USA) and run on a Luminex-100 cytometer (Luminex Corpo-
ration, Austin, TX, USA), equipped with StarStation software
(Applied Cytometry Systems, Dinnington, UK). The assay was
performed with slight modification from the manufacturer’s
recommendation. Briefly, assays were done in a 96-well U plate
at room temperature. Mixes of beads were incubated for 2 hours
with a standard, samples, or blank in a final volume of 50 mlf o r
2 hours under continuous shaking. Beads were washed twice and
incubated with cocktail of biotinylated antibodies (25 ml/well) for
1 hour. After removal of excess biotinylated antibodies, Strepta-
vidin-PE was added for 30 minutes. The plate was then washed
and analyzed. The lower detection limit of the assays was 3 pg/
ml, 5 pg/ml, 10 pg/ml, 5 pg/ml and 10 pg/ml for IL-5, IL-10,
IL-13, IFN-c and TNF-a, respectively. Samples with concentra-
tions below the detection limit were given the value of this
threshold.
Follow-up for BCG scar and in vivo PPD response
All LBW children were visited at home and examined for BCG
scar and in vivo PPD response at 2 and 6 months of age. In four of
six study area districts NBW children were examined for BCG
scar and in vivo PPD response when they reached 2 and 6 months
of age. At the home visits a trained nurse documented health
status and vaccination status. She measured the size of the scar
following BCG vaccination. Subsequently, 0.1 ml of Tuberculin
PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) was
injected intradermally on the ventral side of the forearm. Between
48 and 72 hours later, the child was visited again, and the
induration was measured by a trained field worker using track-
ball technique [9]. Size of scar and induration was defined as the
average of the height and the width measured to nearest
millimeter with a transparent ruler. Children with a measurable
scar were categorized as ‘‘scar-positive’’. Children with a mean
diameter of the induration $2 mm were categorized as ‘‘PPD-
positive’’. Children who had taken chloroquine within seven days
prior to the visit were excluded from the PPD analysis, since
chloroquine treatment is known to suppress PPD reaction [10].
These children were retained in the analysis of scar reaction since
we considered it unlikely that current chloroquine treatment
would have affected the scar formation. Children who had
received BCG vaccination less than 30 days prior to the visit or
with known exposure to tuberculosis in the household within the
previous 6 months (information only available for NBW
population) were excluded. Children with PPD reactions
.10 mm were referred to a medical doctor to be further
examined for tuberculosis (TB).
Statistical analysis
All statistical analysis was performed in Stata 10.0.
In vitro PPD response. Cytokine levels were not normally
distributed. The crude cytokine levels were first compared in a
univariate analysis using non-parametric Mann-Whitney U tests,
and the results were provided in the figures of the distribution of
cytokine levels in the different groups (Figures 2 and 3).
Subsequently, the frequency of low and high cytokine
producers in BCG and BCG+OPV recipients was compared in
Poisson regression model with robust variance estimates [11]
using the median cytokine level in the total population as cut off
for low and high responder. Thus, the relative measure is a
prevalence ratio (PR). The study population was divided into 4
groups according to the birth weight and whether OPV was given
together with BCG at birth (Table 1). As the periods with lack of
OPV fell primarily in the dry season (from December to May), all
children who had received BCG+OPV had been vaccinated in
the rainy season (June to November). The two LBW groups were
similar with respect to age and sex. However, MUAC at
enrolment was larger in the BCG+OPV group compared with
the BCG group, and they had received more OPV and more
diphtheria-tetanus-pertussis (DTP) vaccines (recommended at age
6, 10 and 14 weeks) between enrolment and blood sampling
(Table 1). The two NBW groups were similar with respect to age
and MUAC at enrolment (Table 1). However, they were
significantly different with regard to sex, the NBW BCG+OPV
group having fewer boys. The two groups also differed
significantly with regard to vaccinations received between
enrolment and blood sampling (more OPV and less DTP in
the BCG+OPV group). All further analyses were adjusted for age,
sex, month of enrolment, MUAC at enrolment, and vaccinations
between enrolment and blood sampling.
BCG scar and in vivo PPD response. PPD response (yes/
no) and scar response (yes/no) were analyzed as prevalence data
using a Poisson regression model with robust variance estimates
providing prevalence ratios (PR) [11]. Children with a PPD
response above 15 mm were excluded from the analyses as they
had potentially been exposed to TB. There were no such children
among LBW children. Among NBW children one boy
(BCG+OPV) had a PPD response above 15 mm at age 2
months and was excluded from further analyses. At age 6
months, one boy (BCG+OPV) and one girl (BCG), had a PPD
response above 15 mm and were excluded from the 6 month-
analysis. As in the cytokine analysis, there was a clear overweight
of children who had received BCG+OPV in the rainy season,
though there was more variation because the follow-up for PPD/
scar had been conducted throughout 2004 (Figure 1). Among
LBW infants, the BCG+OPV recipients only differed from the
BCG only recipients with regard to season (Table 2). Among NBW
infants, the two groups also differed with regard to MUAC at
enrolment, and number of OPV received between enrolment and
the PPD/Scar assessment (Table 2). We adjusted the analyses for
sex, season (the larger variation in this analysis compared with the
cytokine analysis allowed us to control for season rather than
month), MUAC, and subsequent vaccinations. As in previous
studies of PPD responses, the reading of the PPD reaction differed
significantly by the assistant doing the reading and the analyses of
PPD responses were therefore furthermore adjusted for assistant.
Among PPD responders and/or scar reactors, we analyzed the size
of the reaction in linear regression models controlling for the same
potential confounders.
OPV Reduces BCG Responses
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In vitro PPD response
This analysis included 61 LBW infants who had been
randomized to early BCG; 33 who had not received OPV at
birth together with BCG and 28 who had. Furthermore, 248
NBW infants who had been randomized to placebo; 69 who had
not received OPV and 179 who had were included.
Influence of OPV on cytokine responses to PPD in LBW
infants
When OPV was given together with BCG, there was a
significant down regulation of IL-5, IL-13, and IFN-c in response
to PPD as compared to the group of infants who had received
BCG only (Figure 2)(Table 3). IL-10 to PPD was higher in LBW
infants who had received BCG together with OPV in the crude
Figure 2. PPD stimulated IFN-c (A), IL-5 (B), IL-13 (C), TNF-a (D) and IL-10 (E) production in low birth weight BCG (LBW BCG) and
BCG+OPV vaccinated (LBW BCG+OPV) infants. One dot represents one individual. Horizontal lines represent medians.
doi:10.1371/journal.pone.0010328.g002
Figure 3. PPD stimulated IFN-c (A), IL-5 (B), IL-13 (C), TNF-a (D) and IL-10 (E) production in normal birth weight BCG (NBW BCG) and
BCG+OPV vaccinated (NBW BCG+OPV) infants. One dot represents one individual. Horizontal lines represent medians.
doi:10.1371/journal.pone.0010328.g003
OPV Reduces BCG Responses
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(Table 3). There were no significant differences in TNF-a to PPD
between the two groups (Figure 2)(Table 3).
Influence of OPV on cytokine responses to PPD in NBW
infants
In the unadjusted analysis IFN-c responses to PPD appeared
depressed and IL-10 responses increased when OPV was given
with BCG (Figure 3). In the adjusted analysis, the IFN-c levels to
PPD were significantly lower in BCG+OPV compared with BCG
only vaccinated infants and there was a similar tendency for IL-13
(Table 3).
Influence of OPV on cytokine responses to PPD in all
infants
In a pooled analysis of LBW and NBW infants, receiving OPV
with BCG at birth was associated with significantly lower IL-13
and IFN-c in responses to PPD; the adjusted PRs (furthermore
adjusted for being LBW) were 0.64 (0.41–0.98)(p=0.041), and
0.51 (0.33–0.80)(p=0.004), respectively. The IL-10 response to
PPD tended to be lower as well (0.61 (0.36–1.01), p=0.054).
BCG scar and in vivo PPD response
Among LBW infants enrolled in 2004, 250 BCG recipients were
visited; 104 had received BCG+OPV, 146 BCG only. We
obtained a scar reading in 231 children at age 2 months and
200 children at age 6 months and a valid PPD assessment of 202 at
age 2 months, and 170 at age 6 months. Among NBW infants
enrolled in 2004, 540 placebo recipients had their BCG scar and
PPD response assessed once or more; 287 had received
BCG+OPV; 253 BCG only. We obtained a scar reading in 438
children at age 2 months and 428 children at age 6 months and a
valid PPD assessment of 379 at age 2 months, and 327 at age 6
months.
Influence of OPV on PPD/Scar responses in LBW
infants. At age 2 months, receiving OPV with BCG at birth was
associated with a borderline significantly lower likelihood of being
PPD positive (Table 4). There was no association with size of the
reaction among the few children who had a positive reaction.
Almost all children were scar positive, and there was no association
between OPV at birth and being scar positive (Table 5), or the size
of the scar among scar positives (data not shown).
At age 6 months, the lower likelihood of being PPD positive
(Table 4) was no longer significant for the OPV group and there
was no association with size of the reaction among the few children
who had a positive reaction. Almost all children were scar positive,
and there was no association between OPV at birth and being scar
positive (Table 5), or the size of the scar among scar positives (data
not shown).
Influence of OPV on PPD/Scar responses in NBW
infants. At age 2 months, receiving OPV with BCG at birth
was not associated with the likelihood of being PPD positive
(Table 4), nor was it associated with the size of the response among
children with a positive response (data not shown). Adjusted for
potential confounders, children who had received OPV at birth
had a lower likelihood of developing a BCG scar (Table 5).
Receiving OPV at birth was negatively associated with the size of
the scar among those who had a scar (regression coefficient 20.36
(20.57—0.15); p=0.001).
Table 2. Description of the scar and PPD study population.
Group N (boys/girls)
Vaccinated in
rainy season
Median MUAC at
vaccination (10–90
centiles)
Received OPV
between
vaccination and
PPD assessment
Received DTP
between
vaccination and
PPD assessment
Median age at
sampling (10–90
centiles)
Low-birth-weight infants
BCG only 146 (57/89) 49 (34%) 82 mm (70–88) 61 (42%) 103 (71%) 65 days (57–79)
BCG+OPV 104 (43/61) 66 (63%) 82 mm (70–90) 47 (45%) 74 (71%) 64 days (59–75)
Normal-birth-weight infants
BCG only 253 (143/110) 74 (29%) 96 mm (88–110) 135 (53%) 230 (91%) 63 days (54–82)
BCG+OPV 287 (146/141) 228 (79%) 100 mm (88–112) 184 (64%) 257 (90%) 64 days (55–78)
doi:10.1371/journal.pone.0010328.t002
Table 1. Description of the cytokine study population.
Group N (boys/girls)
Vaccinated in
rainy season
Median MUAC
at BCG vaccination
(10–90 centiles)
Received OPV
between
vaccination and
blood sample
Received
DTP between
vaccination
and blood sample
Median age
at sampling
(10–90 centiles)
Low-birth-weight infants
BCG only 33 (11/22) 15 (45%) 82 mm (70–88) 3 (9%) 2 (6%) 44 days (38–49)
BCG+OPV 28 (8/20) 28 (100%) 82 mm (70–94) 17 (61%) 7 (25%) 48 days (34–56)
Normal-birth-weight infants
BCG only 69 (44/25) 12 (17%) 100 mm (88–112) 24 (35%) 20 (29%) 43 days (37–59)
BCG+OPV 179 (77/102) 179 (100%) 100 mm (88–108) 122 (68%) 26 (15%) 42 days (36–54)
doi:10.1371/journal.pone.0010328.t001
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associated with the likelihood of being PPD positive (Table 4) or
the size of the PPD reaction (data not shown). Almost all children
had a scar at age 6 months and receiving OPV at birth was not
associated with the likelihood of being scar positive (Table 5) or the
size of the scar (data not shown).
Influence of OPV on PPD/Scar responses in all
infants. In a pooled analysis of LBW and NBW infants,
receiving OPV with BCG at birth was associated with
significantly lower likelihood of being PPD positive at age 2
months, the PR being 0.75 (0.58–0.98), p=0.033. OPV with BCG
was not associated with size of the PPD reaction (data not shown).
Table 3. Comparison of the frequency of cytokine responders in children vaccinated with BCG and with BCG+OPV.
Response to PPD Proportion of high responders (%)
Prevalence Ratio (95% CI)
BCG+OPV versus BCG only
Adjusted Prevalence Ratio (95% CI)
BCG+OPV versus BCG only
BCG+OPV BCG only
Low-birth-weight infants
(N=28) (N=33)
IL-5 9 (32%) 21 (64%) 0.51 (0.28–0.92) 0.56 (0.28–1.12)
IL-10 17 (61%) 11 (33%) 1.82 (1.03–3.23) 0.46 (0.14–1.49)
IL-13 13 (46%) 23 (70%) 0.67 (0.42–1.06) 0.51 (0.22–1.16)
IFN-c 12 (43%) 24 (73%) 0.59 (0.36–0.95) 0.40 (0.15–1.09)
TNF-a 13 (46%) 20 (61%) 0.77 (0.47–1.25) 2.25 (0.74–6.85)
Normal birth-weight infants
(N=179) (N=69)
IL-5 83 (46%) 46 (58%) 0.80 (0.62–1.03) 0.73 (0.42–1.26)
IL-10 96 (54%) 31 (45%) 1.19 (0.89–1.60) 0.63 (0.32–1.21)
IL-13 82 (46%) 36 (52%) 0.88 (0.67–1.16) 0.66 (0.38–1.15)
IFN-c 78 (44%) 41 (59%) 0.73 (0.57–0.95) 0.54 (0.30–0.97)
TNF-a 87 (49%) 34 (49%) 0.99 (0.74–1.31) 0.88 (0.40–1.95)
Adjusted for age, sex, MUAC and month of enrolment, subsequent vaccinations.
doi:10.1371/journal.pone.0010328.t003
Table 4. The effect of receiving OPV with BCG at birth on the likelihood of having an in vivo response to PPD at age 2 months and
6 months.
ALL CHILDREN
CRUDE PR (95% CI)
BCG+OPV VERSUS BCG ONLY
ADJUSTED PR (95% CI)
BCG+OPV VERSUS BCG ONLY
Positive/all (%)
Low-birth-weight infants
2 months
BCG+OPV 7/87 (8%) 0.49 (0.21–1.11) 0.43 (0.18–1.02)**
BCG only 19/115 (17%)
6 months
BCG+OPV 17/71 (24%) 0.85 (0.50–1.43) 0.65 (0.39–1.13)
BCG only 28/99 (28%)
Normal-birth-weight infants
2 months
BCG+OPV 70/208 (34%) 0.81 (0.62–1.05) 0.83 (0.62–1.09)
BCG only 71/170 (42%)
6 months
BCG+OPV 56/167 (34%) 1.01 (0.74–1.38) 1.09 (0.75–1.59)
BCG only 52/157 (33%)
Adjusted for sex, MUAC and season of enrolment, subsequent vaccinations and assistant.
**P=0.056.
doi:10.1371/journal.pone.0010328.t004
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likelihood of being scar positive (0.95 (0.91–1.00), p=0.057).
Among scar positive children, OPV was associated with
significantly reduced scar size, the regression coefficient being
20.24 (20.43—0.05), p=0.012 (Figure 4). No significant
differences were seen at age 6 months.
Discussion
This study is the first to demonstrate that mucosal administra-
tion of OPV simultaneously with intradermal BCG vaccination
may have profound immunological consequences. By comparing
immune responses of infants who had received BCG at birth either
with or without OPV, we observed that OPV had a significant
suppressing effect on Th1 and Th2 responses to PPD. These in vitro
findings were paralleled by findings of significantly reduced in vivo
responses to PPD, a tendency for less BCG scars, and significantly
reduced BCG scar size among those who developed a scar.
Strengths and weaknesses
Though OPV is widely used, little is known regarding the
cellular immune responses following vaccination, in particular its
non-specific immune responses to un-related stimuli. The effect of
OPV could be studied in the present study due to a temporary
shortage of the vaccine in Guinea-Bissau during several periods of
2004. The shortage occurred in a period when two trials,
examining among other things the immune responses of
newborns, were being conducted. It was therefore possible to
study in a relatively unbiased manner the effect of OPV on the in
vitro response to PPD, as well as the effect on two markers of BCG
immunity: PPD responses and BCG scarification.
Strengths of our study include the design; it was mainly logistic
factors which determined whether the children would receive
OPV or not. Despite this, there were some clear differences
between the children who did or did not receive OPV at birth for
instance with regard to season of vaccination, anthropometrics at
inclusion, and other vaccines received. We conducted our analyses
with and without adjustment for these co-variables, and indeed
noted that the crude estimated changed considerably when we
included the other variables as evidence of confounding. We
cannot exclude that there is considerable residual confounding due
to for instance the burden of maternal infectious diseases, other
vaccines received or nutritional status. Especially, residual
confounding by season could be a problem. A recent study in
Malawi found that in vitro IFN-c response to PPD varied strongly
by season, being lowest in the warm and rainy season as compared
with the cool and dry season and the hot and dry season [12]. In
Guinea-Bissau there are two distinct seasons. Our periods without
OPV coincided with the dry season. Hence, we have largely
compared children who received OPV in the rainy season with
children who received no OPV in the dry season. If the IFN-c
response to PPD was depressed for other reasons in the rainy
Table 5. The effect of receiving OPV with BCG at birth on the likelihood of being scar positive at age 2 and 6 months.
ALL CHILDREN
PR (95% CI) BCG+OPV
VERSUS BCG ONLY
ADJUSTED PR (95% CI)
BCG+OPV VERSUS BCG ONLY
Positive/all (%)
Low-birth-weight infants
2 months
BCG+OPV 90/97 (93%) 1.00 (0.93–1.08) 1.00 (0.92–1.08)
BCG only 124/134 (93%)
6 months
BCG+OPV 74/78 (95%) 0.98 (0.92–1.04) 0.98 (0.92–1.05)
BCG only 118/122 (97%)
Normal-birth-weight infants
2 months
BCG+OPV 203/227 (89%) 0.95 (0.90–1.00) 0.93 (0.87–0.99)**
BCG only 198/210 (94%)
6 months
BCG+OPV 217/227 (96%) 0.98 (0.95–1.02) 0.99 (0.95–1.04)
BCG only 193/198 (97%)
Adjusted for sex, MUAC and season of enrolment, and subsequent vaccinations.
**P=0.015.
doi:10.1371/journal.pone.0010328.t005
Figure 4. Comparison of BCG scar size at age 2 months
between infants who got or did not get OPV with BCG at birth.
doi:10.1371/journal.pone.0010328.g004
OPV Reduces BCG Responses
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IFN-c response to PPD response in OPV recipients. However, we
found the same results when we limited our analysis to the rainy
season, though the confidence intervals of course became wider
(data not shown). Furthermore, we found depressed in vivo
responses to PPD as well. The PPD data set was larger than the
cytokine data set, and had more seasonal variation and thereby
more power to control adequately for season. The validity of our
findings is supported by the fact that the findings from the LBW
and NBW cohorts consistently pointed in the same direction, and
the pooled analyses provided significant results. Nonetheless, our
findings should be interpreted with caution.
Previously, it has been shown that BCG vaccination given at
birth in either NBW or LBW infants enhanced immune response
to PPD, characterized by elevated IL-5, IL-13 and IFN-c levels (4,
and unpublished data). In the present study, the administration of
OPV at the time of BCG priming at birth, reduced Th1 and Th2
cytokine responses to mycobacterial antigens in LBW infants,
suggesting that OPV down regulated cellular immune responses to
BCG vaccine when the vaccines were administrated at the same
time.
One possible mechanism whereby OPV co administered with
BCG leads to a reduced cellular response to PPD may be
competition of OPV and BCG activated T cells for resources and
space [13,14]. A second possible mechanism is that polio virus
may have specific immune modulatory molecules that down
regulate immune responses to antigens to which immune
responses are being mounted simultaneously [15].
The fact that the downregulation of cytokine production to PPD
as a result of OPV vaccination was more profound in LBW
compared to NBW infants might be due to functional immaturity
of LBW infants. A recent study by Klein et al. showed that after
inactivated polio vaccine, preterm infants had comparable
frequencies of poliovirus specific CD4
+CD45RO
+CD69
+IFN-c
memory T cells but diminished lymphoproliferation compared to
term infants [16]. Furthermore, it is also possible the differences
between LBW and NBW infants were caused by differences in the
genetic make up. A study by Anuradha et al. reported that IFN-c
low producer genotype +874T/A were over represented in BCG
non-responding children [17].
Implications for BCG immunity
There is considerable evidence, both in humans and animals
that IFN-c production is necessary for protective immunity against
mycobacterial disease [18–21] and successful chemotherapy of TB
is associated with augmented IFN-c production [22–24]. Further-
more, it has also been reported that individuals with genetic
abnormalities of the IFN-c receptor are highly susceptible to
intracellular infections [25–27]. Thus, immunity to tuberculosis
might be impaired by the down regulation of this Th1 response in
LBW children receiving OPV at the same time as BCG at birth.
The finding is supported by the fact that we found reduced PPD
responses and reduced BCG scarification and scar size at age 2
months although these are debatable markers for TB immunity.
Interestingly, the differences were no longer significant at age 6
months. It could be speculated that the PPD skin test at 2 months
of age boosted the immune response to BCG and this obliterated
the differences at 6 months. It has previously been reported that
PPD skin test boosts the subsequent skin test reactivity [28]. The
clinical implications of this early depression in immune responses
to BCG need to be addressed in well-designed randomized trials
with sufficient follow-up.
It is worth noticing that the protection induced by BCG against
tuberculosis has been found to be much higher in high-income
countries than in low-income countries. High-income countries
mainly administer inactivated polio vaccine (IPV) at several
months of age. Though many of the BCG-efficacy studies were
done many years ago, before the introduction of OPV at birth, it
may be speculated that the addition of OPV to BCG at birth has
further compromised the protection induced by BCG in low-
income countries.
Conclusions
In summary, we are aware that the study population is small,
and though we were able to control for a number of confounders
there may be residual confounding. However, the potential effect
of OPV on the immune response to BCG vaccine has not been
studied before, and it may seem biologically plausible that the two
vaccines interact with each other. The potentially negative effect of
OPV on the immune response to BCG vaccine should be tested in
a randomized trial.
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